Can China compete in the AI talent war?
The competition for AI talent prompted Meta to reportedly offer sign-on bonuses of US$100 million to lure senior staff from rivals. It feels 'as if someone has broken into our home and stolen something', OpenAI's chief research officer said of the aggressive poaching in a memo to staff obtained by Wired. The latest victim: Apple, which just lost top executive Pang Ruoming to Meta.
It's telling that so many of the superstar players US tech titans are boasting about adding to their rosters are of Chinese origin. Including Pang, eight out of the 12 new recruits to the Meta Superintelligence Labs team graduated from universities on the mainland before pursuing careers abroad. It means that a key driver of the global AI race is an intense scramble for the people building it: Chinese talent.
The outsize role that they play in developing AI systems for its geopolitical rival likely isn't lost on Beijing. In other tech fields where workers hold a knowledge advantage, the government hasn't been afraid of asking them to return home. Authorities have already reportedly restricted travel for some of DeepSeek's employees. Instead of cracking down on immigration, US policymakers must now do more to entice the best and brightest from China and beyond and create an environment where they are likely to stay.
But American business leaders shouldn't assume that the big pay cheques alone will win an international talent contest. Researchers at Harvard University last month said that the number of high-impact scientific publications shows that China dominates in 'raw human capital for AI'. This helps drive indigenous research despite US advantages in computing power and investment. Top workers may still be keen on making money overseas, but that doesn't mean a lot of them won't stay at home.
Separate researchers at Stanford University in May analysed data on the more than 200 authors listed on DeepSeek's technical papers. The firm's success story is 'fundamentally, one of homegrown talent', they found. Half of DeepSeek's team never left China for education or work, and those who did ultimately returned to pursue AI development. This has policy implications for the US.
BT in your inbox
Start and end each day with the latest news stories and analyses delivered straight to your inbox.
Sign Up
Sign Up
China looks at international experience less as a brain drain and more as a way for researchers to acquire knowledge before returning home, the Stanford paper said. The US 'may be mistakenly assuming it has a permanent talent lead'.
It aligns with other data that suggests America has been losing its allure as a destination for top-tier AI researchers. Only 42 per cent of these individuals worked in the US in 2022, compared to 59 per cent in 2019. During that same period, China was closing the gap fast, rising to 28 per cent from 11 per cent.
The Chinese government, meanwhile, has been funding AI labs and research at universities as part of industrial policy. It's not clear how well this investment has paid off, but it has helped incubate talent who went on to support breakthroughs at private companies. One of DeepSeek's keystone papers, for example, was co-authored by scholars at Tsinghua University, Peking University and Nanjing University. In this way, China has been building up an ecosystem of innovation that doesn't centre around poaching individual star players.
Domestic firms are less able to spend so lavishly to attract top talent. US private investment in AI was nearly 12 times the amount in China, according to one analysis. Earlier this year, state-backed news outlet the Global Times reported on the 'high-paying job offers' from DeepSeek, which could amount to annual income of some 1.54 million yuan (S$270,000) per year. It's a significant sum in urban China, but hardly the instant millionaire-minting figures being tossed around in Silicon Valley.
DeepSeek is nonetheless in the midst of a recruiting blitz – one that's trying to attract overseas Chinese AI researchers to come back home. It has posted a spate of roles on LinkedIn, a platform that's not used domestically. As my colleague Dave Lee has written, this is about more than just money, but instead convincing workers that their contribution 'will matter most in the history books'. DeepSeek may be hoping that this pitch will work on homesick Chinese talent.
Ultimately, just under half of the world's top-tier AI researchers come from China, compared to 18 per cent from the US. Many may be seeking opportunities abroad, but Beijing is pulling all its levers to convince at least some to stay at a time when America isn't signalling a warm welcome. Mind-boggling sign-on bonuses from Silicon Valley may be enough to win a cross-border battle for talent, but time will tell if it's enough to win the war. BLOOMBERG
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Straits Times
5 minutes ago
- Straits Times
Washington says China will not let US government employee leave the country
Find out what's new on ST website and app. FILE PHOTO: A Chinese flag flutters on top of the Great Hall of the People, in Beijing, China October 18, 2023. REUTERS/Edgar Su/File Photo WASHINGTON - The U.S. State Department said on Monday that the Chinese government had blocked a U.S. Patent and Trademark Office employee visiting the Asian country in a personal capacity from leaving. "We are tracking this case very closely and are engaged with Chinese officials to resolve the situation as quickly as possible," a State Department spokesperson said. The U.S. Patent and Trademark Office is part of the federal Department of Commerce. The individual's name and whether the person was detained were not disclosed. The Chinese embassy in Washington and the U.S. Commerce Department did not immediately respond to requests for comment. The Washington Post reported on Sunday that a U.S. citizen who works for the Commerce Department had traveled to China several months ago to visit family. The man was being prevented from leaving the country after he failed to disclose on his visa application that he worked for the U.S. government, the newspaper said, citing sources. Beijing has used exit bans on both Chinese and foreign nationals in connection with civil disputes, regulatory enforcement and criminal investigations. Analysts say the tactic is at times used to crack down on local dissent and also as diplomatic leverage in disputes with other nations. Top stories Swipe. Select. Stay informed. World US President Trump 'caught off guard' by Israel's strikes in Syria Singapore LTA seeks tailored solutions to improve Bukit Panjang LRT's maintenance inspections Opinion Singapore's vaping crisis lays bare the drug addiction nightmare for parents Singapore Subsidies and grants for some 20,000 people miscalculated due to processing issue: MOH Multimedia 'It's very sad': She comforts loved ones turned away by inmates Opinion Sumiko at 61: 7 facts about facial skin ageing, and skincare ingredients that actually work Business Why Singapore and its businesses stand to lose with US tariffs on the region Opinion With Shatec cutting back operations, what's next for the hospitality sector? Washington and Beijing have had friction for years over issues ranging from tariffs to the origins of COVID-19 and Taiwan. Chenyue Mao, a Wells Fargo banker, has also been blocked from leaving China. Beijing's foreign ministry said on Monday she was involved in a criminal case and obliged to cooperate with an investigation. Mao was the latest of several executives from foreign corporations to be stopped as they tried to depart China. The U.S. bank suspended all employee travel to China after Mao's exit ban, a person familiar with the matter told Reuters last week, saying Mao was a U.S. citizen. REUTERS
Business Times
5 minutes ago
- Business Times
AstraZeneca vows to spend US$50 billion on US manufacturing, development
[MUNICH/WASHINGTON] AstraZeneca plans to invest US$50 billion in the US before 2030, becoming the latest European pharma company to ratchet up spending in the country ahead of potential tariffs on imported medicines. The investment will go towards manufacturing as well as research and development, Astra said in a statement. It includes US$4 billion for a new facility in Virginia that will make drugs for chronic diseases, Kevin Hassett, director of the US National Economic Council, said on Monday (Jul 21) at an event in Washington, DC. 'With the completion of this investment, substantially all of AstraZeneca's pharmaceuticals sold at the United States will be produced in the United States,' Hassett said. Astra's announcement comes as European drug companies rush to highlight their significant footprints in the US in hopes of mitigating the impact of any potential tariffs from US President Donald Trump. Astra already announced plans in November, a week after Trump's election, to invest US$3.5 billion in the US by the end of 2026, noting at the time that it employs nearly 18,000 people in the country. Since then, European competitors have touted even larger spending plans. Switzerland's Novartis in April announced plans for US$23 billion in US-based infrastructure spending, while cross-town rival Roche Holding said it would invest US$50 billion. In May, French drugmaker Sanofi announced intent to invest at least US$20 billion in the US by 2030. Pascal Soriot, who's been chief executive officer of Astra since 2012, has also urged tariff restraint. This spring, he recommended that US officials exempt medicines from tariffs, arguing that tax incentives are a better way to attract investment in drug development and manufacturing. BT in your inbox Start and end each day with the latest news stories and analyses delivered straight to your inbox. Sign Up Sign Up Trump has proposed various timelines for tariffs on pharmaceuticals, most recently floating duties that would be imposed as soon as Aug 1. The president said that he expects to give companies a year to bring manufacturing to the US before imposing tariffs as high as 200 per cent. Meanwhile, Soriot has raised concerns in the UK about his commitment to the home country. He has long complained about the UK's regulatory environment, which he says is a threat to hold back the UK from staying competitive with the US and China. In January, Astra abandoned plans for a £450 million (S$777 million) vaccine manufacturing plant in Liverpool. The company operates 17 manufacturing sites in 12 US states. Earlier this month, British paper The Times reported that Soriot is considering moving the company's stock listing to the US. That would be a major blow to the UK's equity markets, which have endured similar defections from other companies in recent years. Under Soriot's leadership, Astra's market value has more than tripled as the company has become a global powerhouse in cancer medicines. It's also built up a significant drug pipeline for other areas including cardiovascular, renal and metabolic diseases. BLOOMBERG
Business Times
5 minutes ago
- Business Times
Winter is coming for oil – and not in a positive way
The oil market is deceptively calm. Below the apparent tranquility lies an underappreciated transformation that has slowly reshaped the market over the last 25 years – because the arrival of China and India as big consumers has not just given an enormous boost to demand, it has also altered the market's seasonality. And that matters a lot this year. Until recently, global oil demand peaked every year with the arrival of the Northern Hemisphere's winter. As temperatures dropped from October, heating oil and kerosene consumption spiked from the US to Germany to Japan. Hence, as recently as 2014, the fourth quarter still marked the annual high for crude demand and, typically, prices. Since then, the seasonality has flipped: Now, the third quarter sees higher demand and prices. The shift means the market is now at its tightest from July to September, rather than October to December. While one-time events can still have an effect – the 2008 global financial crisis, for example, or the Covid-19 pandemic that started in early 2020 – looking over a long enough timescale reveals the change clearly. Because it happened incrementally over a quarter of a century, it often does not get the attention it deserves. The change has three notable features. First, consumption of winter fuels including heating oil and kerosene is on a structural decline in the industrialised world, replaced by natural gas and electricity. BT in your inbox Start and end each day with the latest news stories and analyses delivered straight to your inbox. Sign Up Sign Up Back in 1990, about 17 per cent of American families heated their homes by burning some kind of refined petroleum product; today, that share has fallen to 9 per cent. The collapse in demand for heating oil in Europe is even more pronounced. At the same time, jet fuel consumption in those regions, which typically peaks during the summer holidays, is growing fast. Second, oil demand in fast-growing emerging nations follows different seasonal patterns, partly because of their locations closer to the Equator, but also because of the larger role of their year-round industrial oil consumption. While industrialised nations mostly abandoned oil-fired power stations after the 1970s energy crisis, some emerging market countries, particularly in the Middle East, burn lots of crude for electricity generation and water desalination. At the peak last summer, Saudi Arabia burned more than 800,000 barrels a day to generate electricity for air-conditioning – more than the daily total petroleum demand of Belgium. So this year, global third-quarter oil demand will be 500,000 barrels a day higher than fourth-quarter consumption. In a dataset going back to 1991, the current year will mark only the fifth time when winter demand will be lower than summer consumption. Despite rising production from the Opec+ (Organization of the Petroleum Exporting Countries and its allies) cartel, oil prices have stabilised in recent weeks at just over US$65 a barrel – about US$10 above the lows seen in early May. If anything, the physical oil market even feels a bit tight. It helps that China has mopped up much of the oil surplus, putting in May and June barrels into its expanding strategic and commercial stockpiles. But the squeeze will prove temporary; put another way, the market is defying gravity. Because of shifting seasonality, the Northern Hemisphere's summer is now the tightest period of the year. Winter – and an accompanying decrease in demand – is coming. For now, the few remaining oil bulls have a few straws of hope to cling to. Global crude refinery intake is rising swiftly this month, and looks set to peak in August at a record 85.4 million barrels a day – enough to absorb the series of Opec output increases. As a result, global oil stocks are not increasing meaningfully near where it matters most to the market: the pricing points in north-western Europe, home of the Brent benchmark, and the central area of the US, home to the West Texas Intermediate yardstick. But by October, when all of the cartel's supply hikes will have arrived, along with extra oil from Brazil, Guyana and Canada, refinery throughput will drop to 81.7 million barrels a day, according to the International Energy Agency. The difference – 3.7 million barrels a day – is equal to a couple of mid-sized Opec nations. Even if China continues stockpiling as much as it has done over the last two months, the surplus would be so large that oil will flow into inventories elsewhere, including near the pricing points on both sides of the Atlantic. For sure, the market – and I – may be wrong about demand, supply or both. The expected oil surplus during the now seasonally weaker fourth quarter may be smaller than anticipated. Still, on paper, the glut is so big that even if it turns out to be a bit smaller, it would still be enough to put a lot of downward pressure on the market. As I said, winter is coming for the oil market. BLOOMBERG The writer is co-author of The World for Sale: Money, Power and the Traders Who Barter the Earth's Resources
